Amphastar Pharmaceuticals

Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company.[2] It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.[3]

Amphstar Pharmaceuticals, Inc.
TypePublic
HeadquartersRancho Cucamonga, California, United States
Key people
  • Mary Z. Luo
  • (Chairman of the Board)
  • Jack Yongfeng Zhang
  • (CEO)
RevenueIncrease US$ 498.9 million (2022)
Increase US$ 107.4 million (2022)
Increase US$ 91.3 million (2022)
Total assetsIncrease US$ 741.9 million (2022)
Total equityIncrease US$ 528.6 million (2022)
Number of employees
1,615
WebsiteAmphastar.com
Footnotes / references
[1]

One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic.[4] In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.[4]

In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.[5]

In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn.[6][7]

See also

References
  1. "U.S. SEC: Form 10-K, Amphstar Pharmaceuticals, Inc". U.S. Securities and Exchange Commission. Retrieved July 31, 2023.
  2. "Amphastar Pharmaceuticals, Inc. (AMPH)". NASDAQ.com. NASDAQ OMX Group. Retrieved 3 January 2016.
  3. "Profile:Amphastar Pharmaceuticals Inc (AMPH.O)". Reuters.
  4. Arsalan, Arif (February 21, 2017). "After steering through a controversy over soaring price of naloxone, FDA rejects Amphastar's intranasal version". Endpoints.
  5. Tyler, Eleanor (March 21, 2018). "Amphastar Patent Win Boosts Momenta, Sandoz Antitrust Case". Bloomberg. Retrieved March 24, 2018.
  6. "Eli Lilly Divests Low Blood Sugar Drug Baqsimi To Amphastar For $500M Cash". Yahoo Finance. Retrieved 2023-04-26.
  7. "Amphastar buys Baqsimi to build out specialty med offering". www.thepharmaletter.com. Retrieved 2023-04-26.
  • Official website
  • Business data for Amphstar Pharmaceuticals, Inc.:
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.